Core Insights - The 2025 ASCO Annual Meeting will take place from May 30 to June 3 in Chicago, showcasing significant advancements in innovative drug development from Chinese pharmaceutical companies [1][5] - Multiple drugs with "first-in-class" or "best-in-class" potential have been selected for oral presentations, highlighting the R&D capabilities of Chinese biotech firms [1] Group 1: Company Highlights - Innovent Biologics has seven studies selected for oral presentations, including IBI363 (PD1xIL2 bispecific antibody) with clinical data on non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and malignant pleural mesothelioma (MLN) [1] - China Biologic Products has twelve studies selected, with four classified as "latest breakthrough abstracts" (LBA), notably the combination of bemarituzumab and anlotinib for first-line treatment of NSCLC [1] - Kelun-Biotech will present six research outcomes, focusing on SKB264 (TROP2 ADC), A167 (PD-L1 monoclonal antibody), and A400 (RET inhibitor) [2] Group 2: Drug Development Focus - Antibody-drug conjugates (ADCs) are a major focus for domestic pharmaceutical companies at this year's meeting, with several companies showcasing their ADC products [2] - Baiyuntianheng's bispecific ADC BL-B01D1 (EGFRxHER3) will present Phase I clinical data for small cell lung cancer (SCLC) and NSCLC [3] - Zai Lab's ZG006 (DLL3xCD3 tri-antibody) will release Phase II dose expansion data for SCLC patients, along with updates on other dual-target antibodies [3] Group 3: Key Clinical Data - The combination therapy of vidutolimab and trastuzumab for HER2-positive gastric cancer will be presented in a rapid oral report [4] - The c-MET ADC RC108 will also update its progress during the meeting [4] - The ASCO 2025 meeting is positioned as a crucial platform for Chinese innovative drug companies to showcase their breakthroughs in key indications, further promoting the internationalization of domestic innovations [5]

Core Viewpoint - Innovent Biologics is set to present clinical data for its bispecific antibodies and ADC molecules at the ASCO Annual Meeting 2025, highlighting advancements in cancer treatment, particularly with IBI363 and IBI343 [1][2] Group 1: Clinical Presentations - IBI363 has three indications accepted for oral presentations: melanoma, colorectal cancer (CRC), and non-small cell lung cancer (NSCLC), showcasing the attention on PD-1-based immunotherapy [2] - The Phase 1b data of IBI343 in pancreatic cancer will also be presented, reinforcing its potential in a challenging therapeutic area [2] - The presentations are scheduled between May 30 and June 3, 2025, in Chicago, Illinois [1] Group 2: Presentation Details - IBI363's efficacy and safety results in advanced acral and mucosal melanoma will be presented on May 31, 2025 [3] - The efficacy and safety of IBI363 in advanced colorectal cancer will be discussed on June 1, 2025 [4] - IBI363's application in advanced immunotherapy-treated NSCLC will be presented on June 3, 2025 [4] Group 3: Company Overview - Innovent Biologics, founded in 2011, focuses on developing high-quality biopharmaceuticals for various diseases, including cancer [12] - The company has launched 15 products and has multiple assets in various stages of clinical trials, indicating a robust pipeline [12] - Innovent collaborates with over 30 global healthcare companies, enhancing its research and development capabilities [12]